RNA

New Look at Breast Cancer Cell Line Sheds Light on Structural Complexity

One year ago   |   By Pacific Biosciences

In an exciting paper that made the cover of Genome Research , scientists from Cold Spring Harbor Laboratory and collaborating institutions report the genome sequence and transcriptome of a commonly used breast cancer cell line. They determined that the cell line harbors far more structural variants than previously thought with results that call into question cancer genome analysis based solely on short-read sequencing data.
In “ Complex rearrangements and oncogene amplifications revealed by long-read DNA and RNA sequencing of a breast cancer cell line ,” lead author Maria Nattestad, senior...
Read more ...

 


Search by Tags

   RNA      Research      Paper      Cancer      DNA      Genomics      Genome      Blog      Breast cancer      Structural variation  


World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

2nd International Conference on Tissue Science and Regenerative Medicine

This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...

Gene Therapies: The Pipeline Towards a New Era for Patients

Gene Therapies: The Pipeline Towards a New Era for Patients

On Tuesday morning at the BIO Investor Forum , leaders from top companies at the forefront of gene therapy innovation assembled to discuss successful approaches, challenges in... Read more ...

Biogen Reverses Course on Alzheimer's Drug Analysis, Plans FDA Filing

Biogen Reverses Course on Alzheimer's Drug Analysis, Plans FDA Filing

Six months after Biogen stopped work on a closely watched experimental Alzheimer's disease treatment, the neuroscience drug developer is reviving it with plans to file for FDA... Read more ...

Researchers Identify Cells that Drive Human Skin Aging

Researchers Identify Cells that Drive Human Skin Aging

Mayo researchers report for the first time that melanocytes in skin drive aging of that organ. The information clarifies a mechanism that drives aging in human skin and may... Read more ...

Vertex Stock Up on Quick FDA OK For 3-Drug Cystic Fibrosis Therapy

Vertex Stock Up on Quick FDA OK For 3-Drug Cystic Fibrosis Therapy

The FDA on Monday approved a Vertex Pharmaceuticals cystic fibrosis treatment that combines three drugs, a decision that comes three months after the company submitted its... Read more ...

SeaGen to Seek FDA Nod After Breast Cancer Drug Hits Goals of Key Study

SeaGen to Seek FDA Nod After Breast Cancer Drug Hits Goals of Key Study

An experimental breast cancer drug from Seattle Genetics is headed for FDA review after the company reported a pivotal clinical trial met its main goals. The company has been... Read more ...

Chemical 'vaccine' helps plants repel pathogens

When plants come under attack from invading bacteria, viruses or fungi, they mount a two-pronged response, producing both offensive chemicals to kill invaders and defensive... Read more ...

Evotec brings early stage accelerator model to Israel

Evotec has expanded its model for accelerating early-stage academic research to Israel. The creation of the latest outpost of the BRIDGE model sees Evotec team up with Integra... Read more ...

Novartis bets $80M on Pliant's preclinical NASH prospect

Novartis has put up $80 million to land the global license to Pliant Therapeutics' preclinical nonalcoholic steatohepatitis asset and three additional candidates. The NASH... Read more ...

Guest Editorial for the ACM International Conference on Bioinformatics...

The six papers in this special section were presented at the ACM Conference on Bioinformatics, Computational Biology, and Health Informatics in 2017. Read more ...

Does Relaxing the Infinite Sites Assumption Give Better Tumor Phylogenies?...

Most of the evolutionary history reconstruction approaches are based on the infinite sites assumption, which states that mutations appear once in the evolutionary history. The... Read more ...